BJDX

Bluejay Diagnostics Inc

• TipRanks·1d ago

  Bluejay Nears Completion of Pivotal SYMON-II Sepsis Trial

• Reuters·1d ago

  Bluejay Diagnostics enrolls 624 patients in SYMON-II pivotal Symphony IL-6 trial

• TipRanks·1d ago

  Bluejay Diagnostics reaches 624 patient enrollment in Symphony clinical trial

• Reuters·1d ago

  BLUEJAY DIAGNOSTICS, INC. ANNOUNCES COMPLETION OF 624 PATIENT ENROLLMENTS IN SYMON-II PIVOTAL CLINICAL TRIAL

• TipRanks·03/17 22:05

  Bluejay Diagnostics Announces Insider-Funded Private Stock Placement

• Reuters·03/17 21:30

  Bluejay Diagnostics sells 62,500 shares in private placement for USD 125,000

• TipRanks·03/16 10:29

  Bluejay Weighs Proposed Therapeutic Acquisition, Reaffirms Symphony Focus

• TipRanks·03/12 16:44

  Bluejay Advances Symphony IL-6 Sepsis Diagnostic Program

• Reuters·03/12 10:30

  Bluejay Diagnostics’ Symphony IL-6 sepsis study accepted for SAEM annual meeting presentation

• TipRanks·03/11 13:35

  NorthStrive Fund urges Bluejay to evaluate strategic opportunity

• Reuters·03/11 13:30

  NORTHSTRIVE FUND II LP ISSUES OPEN LETTER TO THE BOARD AND SHAREHOLDERS OF BLUEJAY DIAGNOSTICS

• Reuters·03/11 13:30

  NORTHSTRIVE FUND II: RECOMMENDING BLUEJAY BOARD EVALUATES A STRATEGIC OPPORTUNITY

• Reuters·03/11 13:30

  NORTHSTRIVE FUND II:LETTER RECOMMEND BLUEJAY BOARD REVIEW POTENTIAL ACQUISITION OF PHASE-1-READY THERAPEUTIC ASSET TARGETING REFRACTORY CHRONIC COUGH

• Reuters·03/06 21:03

  Bluejay Diagnostics FY2025 net loss narrows 11% to $6.85 million as interest expense plunges 100% to $0 million

• Reuters·03/06 14:22

  Bluejay Diagnostics Outlines 2026 Plans to Complete SYMON II Study, Advance Toward Regulatory Submission, Scale Manufacturing for Commercialization and Raise Additional Capital